BioMedNewsBreaks Archive - Page 127 of 245

TuesdayJan 10, 2023 10:53 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Begins Trading on Next-Gen Marketplace

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, announced that today at 10 a.m. EST, the company will start trading on Upstream under the ticker symbol JUPW. A revolutionary trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. The company noted that a digital collectible NFT commemorating the dual listing would be available for Upstream participants to claim using the code: JUPW. Through Upstream, investors around the world can invest in JUPW by downloading the Upstream app from their preferred app store and creating an account. Transactions…

MondayJan 09, 2023 12:19 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain barrier to target tumors directly. The inability of anthracyclines to cross the blood-brain barrier has been identified as a major obstacle in treating aggressive brain tumors such as GBM and creates an opportunity for CNS…

MondayJan 09, 2023 11:56 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such as alcohol, as well as the appointments of Dr. Jeremy Chataway, Dr.Ashwin Dhanda and Dr. Anh Lê to its scientific and clinical expert committee. “We are excited about the incorporation of FSD Pharma Australia, where…

MondayJan 09, 2023 10:36 am

BioMedNewsBreaks — MetAlert Inc. (MLRT) Featured in Ludlow Research Analyst Brief

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, spotlighted in a recent Q&A analyst report released by Ludlow Research. In the article, MLRT representations respond to questions, providing an overview of the company and discussing specific topics investors and shareholders might be interested in. The report delved into the company’s recent restructuring, name change and ticker symbol change, with the company stating that “we waited patiently to do this until we had a clean balance sheet and were prepared to take the company to the next level.” The report noted that…

MondayJan 09, 2023 10:28 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates releasing an interim readout from the trial by the end of February 2023, which will provide an initial understanding of the safety and pharmacokinetic (“PK”) profile of the substance in humans. This interim data will…

FridayJan 06, 2023 11:36 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the industry. The event is known for gathering together global industry leaders with officials from emerging fast-growth companies along with innovative technology creators and members of the investment community. FSD Pharma director and CEO Dr. Lakshmi…

FridayJan 06, 2023 10:10 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept study. The study evaluated BVXV’s innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy; results indicate that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax’s NanoAb was “virtually eliminated” and significantly less than the amount of virus detected in the placebo group. Specifically, hamsters infected with SARS-COV-2 that were treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies had more than 30 times…

ThursdayJan 05, 2023 1:14 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Receives Key Patent from European Patent Office

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has been issued a patent by the European Patent Office. The company received notification that the patent was issued covering the company’s flagship technology that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device. This patent offers protection in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The company noted that the newly issued patent “expands on HeartBeam’s granted and pending core patents…

ThursdayJan 05, 2023 12:33 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the Virtual Investor 2023 “Companies to Watch” event. Climaco’s presentation is scheduled to take place beginning at 10 a.m. ET on Wednesday, Jan. 18, 2023. A live video webcast of the presentation will be available on the Events page of CNS Pharmaceuticals’ website, and a replay will be available two hours following the live presentation and accessible for 90…

ThursdayJan 05, 2023 12:26 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Issues Shareholder Update

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today issued its year-end shareholder letter. In the update, the company’s CEO and Founder Patrick Bertagna shared insight on the company’s restructuring, branding and efforts to attract new investors and larger customers to execute its growth strategy, as well as the milestones that will shape MetAlert’s future. “We are now taking dramatic steps to align the public-facing (stock) part of the company with the operations and vision of the company. Although the short-term performance of the stock has not been what we…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Begins Trading on Next-Gen Marketplace

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

BioMedNewsBreaks — MetAlert Inc. (MLRT) Featured in Ludlow Research Analyst Brief

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Receives Key Patent from European Patent Office

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’

BioMedNewsBreaks – MetAlert Inc. (MLRT) Issues Shareholder Update

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search